FTC declines to probe PBMs; AstraZeneca wins a round in drug discount battle

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: FTC votes against probing the controversial practices of pharmacy benefit managers By Ed Silverman Mel Evans/AP In a closely watched meeting, the Federal Trade Commission voted against proceeding with a study to examine pharmacy benefits managers. Read More STAT+: AstraZeneca wins another round in an escalating battle over a drug discount program By Ed Silverman Raphael Lafargue/Abaca/Sipa USA via AP A U.S. judge ruled that a federal agency incorrectly threatened AstraZeneca with penalties for curtailing drug discounts to the 340B program. Read More STAT+: Pfizer criticized over patent strategy for Covid-19 pill, despite a deal to broaden access in poor countries By Ed Silverman Pfizer "Pfizer tried to save the day with its MPP license and created a narrative about sharing technology," said Burcu Kilic of Public Citizen. Read More Sponsor content by ICON CLINICAL RESEARCH Advanced clinical solutions powered by healthcare intelligence — delivered seamlessly ICON is the world's largest and most comprehensive clinical research organization, powered by Healthcare Intelligence. Leveraging their human expertise, robust clinical capabilities, and insightful data resources, ICON is expanding the possibilities of clinical research without sacrificing the vital, day-to-day functions of today's CROs. Learn more. Agios wins FDA approval for drug to treat rare form of anemia By Adam Feuerstein Ruby Wallau for STAT The drug, mitapivat, is the first approved treatment for pyruvate kinase deficiency, a rare, inherited disorder. Read More STAT+: In a wily protein that helps cancer spread, researchers see a chance to make immunotherapy more effective By Angus Chen Molly Ferguson for STAT Here’s STAT’s comprehensive guide to TGF-beta, which biopharma companies are trying to target to make cancer immunotherapy more effective. Read More Thursday, February 17, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser